The manufacturing of high-potent active pharmaceutical ingredient (HPAPI) requires stringent safety conditions and containment. Because of the high investment in infrastructure and capabilities, many pharma companies outsource their high potent API needs to Contract Research and Development Organizations (CDMOs). CDMOs such as Aurigene Pharmaceutical Services, are well equipped to support. A usual outsourcing project starts with a chemical entity test to define the occupational exposure limit (OEL). Once the OEL is established, the containment plan is devised to assess the buffer between no effect and effect. This buffer helps in preventing human exposure and avoiding contamination.